Shenhao started after the college entrance examination

Moral kidnapping is a very disgusting trick!

Faced with the moral kidnapping of Neon News official blog, An Liang did not respond directly at all. He directly morally kidnapped four other companies and dragged others into the water, thus fishing in troubled waters.

Positive reply to moral kidnapping?

That’s nonsense!

Everyone else has been morally kidnapped, how can we still be honest and reasonable?

If you are reasonable, others will continue to kidnap you morally!

For example, Neon News' moral kidnapping on the lighthouse, a hardware auxiliary device for the visually impaired, if Anliang was serious about being reasonable, listed the data to show the hardware cost of the lighthouse, R&D cost, etc.

None of this makes sense.

Because Neon News will continue to kidnap people morally!

Now that moral kidnapping has begun, do we still expect the other party to have any morals?

Neon News originally thought that the future graphene official expo would be morally kidnapped, so as to be reasonable, but who knew that the other party would actually do the opposite, and not only did not explain the moral kidnapping, but became a moral kidnapper.

Apple Xia is the most unlucky country!

Apple Xia Guo is obviously a partner of the Dream Future Graphene Technology Group, but now it is also involved in the Dream Future Graphene official blog.

Apple Xia Guo’s official blog account posted a new Weibo post, stating that Apple’s mobile phone research and development requires a lot of funds. Coupled with various taxes and human resource costs, the net profit of Apple’s mobile phones is not too high.

Benz Motors also bluntly stated that material costs are only visible costs, and there are many invisible costs. In the automotive industry, both R&D expenses and safety testing expenses are very high costs.

Benz also smartly brought the lighthouse, saying that the lighthouse's technological content is very high, especially the image processing technology that has reached the world's advanced level, and the corresponding hardware and software research and development costs are probably very high.

Therefore, Dream Future Graphene Technology Group is willing to sell lighthouses at the material cost price, which is definitely a good deed!

Nova's official account on Weibo was originally just a small transparency.

After all, Nova's Zolgensma special medicine is very niche, and it only entered the Xia Kingdom last year. What's more important is that the price is close to 15 million Xia Guoyuan, and 99.9% of the people in the Xia Kingdom cannot afford such a price.

Therefore, Nova Company is a little brother with no presence on Weibo.

This time, the official blog of Dream Future Graphene was involved, and the official blog of Nova Company responded.

……

Nova Company:

@Dreaming of future graphene: @neonjīwen:

Thank you for caring about our Zolgensma special medicine.

First, let’s announce the research and development cost of Zolgensma’s specific drug: US$10.3 billion.

The research and development took a total of 6 years, starting in 2009 until it was completely verified in 2015. In December 2016, it obtained the Bald Eagle Country FDA certification and entered the Bald Eagle Country market.

In 2017, it obtained the European Union drug certification and entered the European market.

It obtained Xiaguo drug certification in 2018 and officially entered the Xiaguo market in 2019.

Our company plans to enter a large range of mainstream markets around the world this year.

Currently, the price of Zolgensma, our company's specific drug for treating hereditary neuromuscular diseases, is US$2.125 million in Bald Eagle Country. Our company has adopted a global unified settlement plan.

To put it simply, according to the current exchange rate between Xia Guoyuan and the US dollar, the price of our company’s Zolgensma specific drug is only less than 14 million.

Although this price is indeed very expensive, our company wants to clarify one thing.

Even though the price of Zolgensma's specific medicine is high, it still cares for the disadvantaged groups.

This is not sophistry on our part.

Before the emergence of the specific drug Zolgensma developed by our company, if you suffered from a hereditary neuromuscular disease, you had no choice but to wait for death.

The incidence rate of hereditary neuromuscular diseases is 1 in 6,000 to 1 in 10,000. This probability is a true random probability. It does not mean that one of 6,000 to 10,000 newborn babies will definitely suffer from hereditary neuromuscular diseases. Every newborn baby has a chance of getting the disease.

Once you are unlucky and suffer from a hereditary neuromuscular disease, before our company develops the specific drug Zolgensma, there is no other option but to wait for death.

Because our company has developed the specific drug Zolgensma, patients have a second choice.

Let us now make an assumption. If our company lowers the price of Zolgensma to 1,400 Xia Guoyuan, what will be the consequences?

The first consequence should be a good thing, because some patients who would otherwise not be able to afford the high cost of medical treatment will be able to gain a new lease of life with Zolgensma.

We can't deny this!

But what are the consequences?

The next consequence was that our medical achievements, which took us six years of research and development and a total investment of US$10.3 billion, were ruined.

Zolgensma's specific drug was only approved for marketing by Bald Eagle Country in December 2016. Our total revenue is less than US$5 billion, and our total profit is even less.

From the current point of view, we are still losing money in developing Zolgensma specific medicine.

If we are asked to reduce the Zolgensma specific drug to 1,400 Xia Guoyuan at this time, and we do so, what about next time?

Yes!

What about next time?

Or is there a next time?

We need to invest a lot of time and money to develop new drugs, and these investments are risky. For example, we spent 6 years and 10.3 billion US dollars to develop Zolgensma, a specific drug. What if it fails?

Although Zolgensma's specific drug was successful, our company can provide a record of ten new drugs that our company failed to develop, with a total cost of more than 50 billion US dollars.

These R&D costs are invisible consumption, and it is impossible for the outside world to even know about them, and we will not take the initiative to publicize them.

Material costs are only a very small part of the cost, and R&D costs are the biggest problem.

We are a commercial company, and commercial companies must pursue profits.

Under the premise of pursuing profits, we will develop life-saving drugs again and again, instead of generating electricity for love.

If it were to generate electricity for love, a large number of specific drugs would not be developed at all, and patients with corresponding diseases would have no choice at all. Aren't they a vulnerable group in the face of disease?

Therefore, it is impossible to reduce the price of our Zolgensma specific drug at present. We need to make profits, and we need more profits, so that we can have enough funds to develop more new drugs for diseases.

Thanks for understanding!

……

————

Update time: January 27, 2021 02:00:07, good night.